FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559156902> ?p ?o ?g. }

• W2559156902 abstract "Abstract Localized pathologic thrombin generation by the tissue factor/factor VII (TF/FVII)-dependent extrinsic pathway of blood coagulation has been suggested to be the key initiator of thrombosis following blood vessel injury and exposure of blood to the subendothelial matrix that contains coagulation/platelet activator matrix proteins, such as collagen and TF. Inherited FVII deficiency (<1% FVII activity) causes severe symptomatic coagulopathy. Yet, there are no data to suggest that it also protects against thrombosis; in fact, the contrary may be true (Giansily-Blaziot et al, Thromb Res. 2012;130:S47). It has been reported that active site-blocked FVIIa (FVIIai) at doses that do not affect the prothrombin time (PT) help restore cyclic flow variations in stenotic carotids of rabbits without affecting clotting times (Cirillo et al., J Thromb Haemost. 2003;1:992). However, in a previous primate study, we could not demonstrate the antithrombotic effect of FVIIai at a dose that caused significant prolongation of the bleeding time in our established baboon model of acute vascular graft thrombosis (Gruber et al., Thromb Res. 2007;119:121-7). The present study was designed to determine the effect of severe yet incomplete experimental FVII deficiency in the same standardized primate model of thrombosis that we used for evaluating the effect of FVIIai. First, baseline (negative control) graft thrombosis was evaluated in baboon studies (N=6), followed by establishing the efficacy of the low molecular weight heparin (LMWH), enoxaparin, at a single 1 mg/kg dose, as positive control. LMWH at this dose was moderately but demonstrably antithrombotic, as assessed by measuring the inhibition of fibrin and platelet deposition in TF- or collagen-coated vascular grafts. Reducing circulating FVII activity levels by 95% to 99% after a 2 week long pre-treatment with a FVII antisense oligonucleotide (FVII ASO) caused significant and sustained (>30 days) systemic anticoagulation, as evidenced by PT increase that reached 2.0-2.6 fold baseline. Surprisingly, fibrin deposition was not affected, and platelet deposition in the thrombogenic devices (N=8) was also not inhibited on collagen-coated grafts, and only marginally inhibited on TF. Treatment with vitamin K antagonists that reduces the level of vitamin K-dependent coagulation enzymes, including FVII, also prolong the PT. Warfarin-induced doubling of the PT is antithrombotic and moderately safe. Yet, in this study where FVII ASO selectively reduced FVII levels, the observed and significant PT prolongation was not associated with anti-fibrin or anti-platelet effects on collagen, and showed an unremarkable anti-platelet effect on TF. We conclude that if the TF/FVII pathway drives the propagation of large vessel thrombi under flow in primates indeed, very low FVII activity (≈1%) must be sufficient to sustain thrombogenesis, supporting the clinical data on deep vein thrombosis, routinely observed in FVII deficiency. Since FVII activity cannot be entirely eliminated without bleeding risks, these data suggest that targeting the TF/FVII pathway with FVII ASO or inhibitors may not be an entirely sound antithrombotic treatment approach. Disclosures Wallisch: Aronora, Inc: Employment. Tucker:Aronora, Inc: Employment, Equity Ownership. Murray:Isis Pharmaceuticals, Inc.: Employment. Crosby:Isis Pharmaceuticals, Inc.: Employment. Monia:Isis Pharmaceuticals, Inc.: Employment. Gruber:Aronora, Inc: Employment, Equity Ownership." @default.
• W2559156902 created "2016-12-08" @default.
• W2559156902 creator A5009460254 @default.
• W2559156902 creator A5011450008 @default.
• W2559156902 creator A5036237322 @default.
• W2559156902 creator A5044334898 @default.
• W2559156902 creator A5050978437 @default.
• W2559156902 creator A5051253113 @default.
• W2559156902 creator A5058226651 @default.
• W2559156902 creator A5060358952 @default.
• W2559156902 creator A5071210838 @default.
• W2559156902 date "2014-12-06" @default.
• W2559156902 modified "2023-09-27" @default.
• W2559156902 title "Lack of Substantial Antithrombotic Effect of Low Circulating Coagulation Factor VII Levels in a Baboon Model of Acute Vascular Graft Thrombosis" @default.
• W2559156902 doi "https://doi.org/10.1182/blood.v124.21.1485.1485" @default.
• W2559156902 hasPublicationYear "2014" @default.
• W2559156902 type Work @default.
• W2559156902 sameAs 2559156902 @default.
• W2559156902 citedByCount "0" @default.
• W2559156902 crossrefType "journal-article" @default.
• W2559156902 hasAuthorship W2559156902A5009460254 @default.
• W2559156902 hasAuthorship W2559156902A5011450008 @default.
• W2559156902 hasAuthorship W2559156902A5036237322 @default.
• W2559156902 hasAuthorship W2559156902A5044334898 @default.
• W2559156902 hasAuthorship W2559156902A5050978437 @default.
• W2559156902 hasAuthorship W2559156902A5051253113 @default.
• W2559156902 hasAuthorship W2559156902A5058226651 @default.
• W2559156902 hasAuthorship W2559156902A5060358952 @default.
• W2559156902 hasAuthorship W2559156902A5071210838 @default.
• W2559156902 hasConcept C126322002 @default.
• W2559156902 hasConcept C186738567 @default.
• W2559156902 hasConcept C203014093 @default.
• W2559156902 hasConcept C2777015399 @default.
• W2559156902 hasConcept C2777151630 @default.
• W2559156902 hasConcept C2777292125 @default.
• W2559156902 hasConcept C2778382381 @default.
• W2559156902 hasConcept C2780868729 @default.
• W2559156902 hasConcept C2780930249 @default.
• W2559156902 hasConcept C54173615 @default.
• W2559156902 hasConcept C71924100 @default.
• W2559156902 hasConcept C89560881 @default.
• W2559156902 hasConcept C98274493 @default.
• W2559156902 hasConceptScore W2559156902C126322002 @default.
• W2559156902 hasConceptScore W2559156902C186738567 @default.
• W2559156902 hasConceptScore W2559156902C203014093 @default.
• W2559156902 hasConceptScore W2559156902C2777015399 @default.
• W2559156902 hasConceptScore W2559156902C2777151630 @default.
• W2559156902 hasConceptScore W2559156902C2777292125 @default.
• W2559156902 hasConceptScore W2559156902C2778382381 @default.
• W2559156902 hasConceptScore W2559156902C2780868729 @default.
• W2559156902 hasConceptScore W2559156902C2780930249 @default.
• W2559156902 hasConceptScore W2559156902C54173615 @default.
• W2559156902 hasConceptScore W2559156902C71924100 @default.
• W2559156902 hasConceptScore W2559156902C89560881 @default.
• W2559156902 hasConceptScore W2559156902C98274493 @default.
• W2559156902 hasLocation W25591569021 @default.
• W2559156902 hasOpenAccess W2559156902 @default.
• W2559156902 hasPrimaryLocation W25591569021 @default.
• W2559156902 hasRelatedWork W126103999 @default.
• W2559156902 hasRelatedWork W2050710926 @default.
• W2559156902 hasRelatedWork W2058157135 @default.
• W2559156902 hasRelatedWork W2101262858 @default.
• W2559156902 hasRelatedWork W2127367952 @default.
• W2559156902 hasRelatedWork W2135967885 @default.
• W2559156902 hasRelatedWork W2138298522 @default.
• W2559156902 hasRelatedWork W2166396480 @default.
• W2559156902 hasRelatedWork W2265447718 @default.
• W2559156902 hasRelatedWork W2306097080 @default.
• W2559156902 hasRelatedWork W2322537776 @default.
• W2559156902 hasRelatedWork W2408937289 @default.
• W2559156902 hasRelatedWork W2409060338 @default.
• W2559156902 hasRelatedWork W2559563016 @default.
• W2559156902 hasRelatedWork W2888279400 @default.
• W2559156902 hasRelatedWork W2898456094 @default.
• W2559156902 hasRelatedWork W2922539873 @default.
• W2559156902 hasRelatedWork W2987100501 @default.
• W2559156902 hasRelatedWork W2999722624 @default.
• W2559156902 hasRelatedWork W3015230913 @default.
• W2559156902 isParatext "false" @default.
• W2559156902 isRetracted "false" @default.
• W2559156902 magId "2559156902" @default.
• W2559156902 workType "article" @default.